Qrativ

Cambridge, United States Founded: 2017 • Age: 9 yrs
AI based drug purposing platform to identify treatments for rare diseases
Annual revenue - Latest available
Total funding $8.3M 1 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 8 Brand Intelligence

About Qrativ

Qrativ is a company based in Cambridge (United States) founded in 2017 by Murali Aravamudan and Andrew Badley. Qrativ has raised $8.3 million across 1 funding round from investors including Matrix. Qrativ operates in a competitive market with competitors including Causaly, ScienceIO, Collaborative Drug Discovery, BioSymetrics and Citelighter, among others.

  • Headquarter Cambridge, United States
  • Founders Murali Aravamudan, Andrew Badley
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $8.3 M (USD)

    in 1 rounds

  • Latest Funding Round
    $8.3 M (USD), Series A

    Jul 14, 2017

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Qrativ

Qrativ has successfully raised a total of $8.3M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.3 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Qrativ

Qrativ has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Matrix.

All
Venture Fund
Investor Description Founded Year Domain Location
Early-stage ventures are funded by the investment firm.
Locked Locked Locked
Premium access

Investor details for Qrativ

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Qrativ

Investments
Premium access

Investment portfolio details for Qrativ

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Qrativ

Premium access

Detailed financials for Qrativ

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Qrativ Comparisons

Qrativ Primary company
Description
AI based drug purposing platform to identify treatments for ...
Location
Cambridge, United States
Founded Year
2017
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Qrativ

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Qrativ

Qrativ operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Causaly, ScienceIO, Collaborative Drug Discovery, BioSymetrics and Citelighter, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
AI-based data-mining tools for scientific evidence discovery are provided.
Locked Locked Locked
Provider of AI solutions transforming medical text into enriched healthcare data
Locked Locked Locked
Biological and chemical data are managed securely in a database.
Locked Locked Locked
Provider of a cognitive computing-based biomedical intelligence platform
Locked Locked Locked
Digital writing solution for K-20 students
Premium access

Detailed competitors of Qrativ

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Qrativ

Premium access

Complete news archive for Qrativ

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Qrativ

Qrativ was founded in 2017.

Qrativ is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Murali Aravamudan is the current CEO of Qrativ. They have also founded this company.

Qrativ is a funded company, having raised a total of $8.3M across 1 funding round to date.

Qrative is a joint venture formed by Mayo Clinic nference to identify treatments for rare diseases using drug purposing approach. The company has developed a propriety drug purposing platform, Darwin.ai, leverages proprietary data from Mayo Clinics (EHRs, prescription diagnosis data, patient-treatment omics) and nferences knowledge synthesis AI platform (data extracted from PubMed, Clinical Trials, etc). The company claims that the drug developers can use its platform to identify uses for their molecules at an early phase of development. The company has got 8.3 million funding from Matrix Capital Management, Matrix Partners, and the Mayo Clinic.

Qrativ's top competitors include Causaly, ScienceIO and BioSymetrics.

Qrativ has 1 investor. Key investors include Matrix.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available